• Araujo AB, Esche GR, Kupelian V, O'Donnell AB, Travison TG, Williams RE et al. (2007) Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 92, 42414247.
  • Barrett-Connor E, Von Muhlen DG & Kritz-Silverstein D. (1999) Bioavailable testosterone and depressed mood in older men: the rancho bernardo study. J Clin Endocrinol Metab 84, 573577.
  • Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS et al. (2010) Testosterone therapy in men with androgen deficiency syndromes: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 95, 25362559.
  • Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E et al. (2011) Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the framingham heart study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 96, 24302439.
  • van Buuren S & Groothuis-Oudshoorn K. (2011) Mice: multivariate imputation by chained equations in r. J Stat Softw 45, 167.
  • Buvat J, Montorsi F, Maggi M, Porst H, Kaipia A, Colson MH et al. (2011) Hypogonadal men nonresponders to the pde5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (tadtest study). J Sex Med 8, 284293.
  • Cavallini G, Caracciolo S, Vitali G, Modenini F & Biagiotti G. (2004) Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology 63, 641646.
  • Daniell HW, Lentz R & Mazer NA. (2006) Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain 7, 200210.
  • Derogatis LR & Palmer A. (1998) The derogatis affects balance scale. In: Evaluating Stress a Book of Resources, Vol. 2. (eds CP Zalaquett & RJ Wood), pp. 89117. Scarecrow Press, Blue Ridge Summit, PA.
  • Dupuy HJ. (1984) The psychological general well-being (pgwb) index. In: Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies (ed NK Wenger), pp. 170183. Le Jacq Publications, New York.
  • Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD & Wicker PA. (1998) Oral sildenafil in the treatment of erectile dysfunction. Sildenafil study group. N Engl J Med 338, 13971404.
  • Hall SA, Esche GR, Araujo AB, Travison TG, Clark RV, Williams RE et al. (2008) Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample. J Clin Endocrinol Metab 93, 38703877.
  • Kouri EM, Lukas SE, Pope HG Jr & Oliva PS. (1995) Increased aggressive responding in male volunteers following the administration of gradually increasing doses of testosterone cypionate. Drug Alcohol Depend 40, 7379.
  • Pope HG Jr, Amiaz R, Brennan BP, Orr G, Weiser M, Kelly JF et al. (2010) Parallel-group placebo-controlled trial of testosterone gel in men with major depressive disorder displaying an incomplete response to standard antidepressant treatment. J Clin Psychopharmacol 30, 126134.
  • Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J & Mishra A. (1997) The international index of erectile function (iief): A multidimensional scale for assessment of erectile dysfunction. Urology 49, 822830.
  • Rosen RC, Cappelleri JC & Gendrano N. 3rd (2002) The international index of erectile function (iief): A state-of-the-science review. Int J Impot Res 14, 226244.
  • Rosen RC, Seidman SN, Menza MA, Shabsigh R, Roose SP, Tseng LJ et al. (2004) Quality of life, mood, and sexual function: A path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms. Int J Impot Res 16, 334340.
  • Seidman SN, Spatz E, Rizzo C & Roose SP. (2001) Testosterone replacement therapy for hypogonadal men with major depressive disorder: A randomized, placebo-controlled clinical trial. J Clin Psychiatry 62, 406412.
  • Shabsigh R, Kaufman JM, Steidle C & Padma-Nathan H. (2004) Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172, 658663.
  • Shores MM, Kivlahan DR, Sadak TI, Li EJ & Matsumoto AM. (2009) A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression (dysthymia or minor depression). J Clin Psychiatry 70, 10091016.
  • Spitzer M, Basaria S, Travison TG, Davda MN, Paley A, Cohen B et al. (2012) Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: A parallel, randomized trial. Ann Intern Med 157, 681691.
  • Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T & Bachand R. (2003) Aa2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 88, 26732681.
  • Travison TG, Araujo AB, Kupelian V, O'Donnell AB & McKinlay JB. (2007) The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J Clin Endocrinol Metab 92, 549555.
  • Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ et al. (2004) Long-term testosterone gel (androgel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89, 20852098.
  • Wang C, Ilani N, Arver S, McLachlan RI, Soulis T & Watkinson A. (2011) Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 75, 836843.
  • Wickham H (2009) Ggplot2: Elegant Graphics for Data Analysis. Springer, New York.